Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barry Brook

Internal Medicine Cincinnati, OH Medical Doctor

NPI 1215993779 CMS profile 654380

4750 E Galbraith Rd Ste 111, Cincinnati, OH 45236

Open in the dashboard

General payments

$11,368

718 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Barry Brook of Cincinnati, OH is reported in the CMS Open Payments database as having received $11,368 across 718 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $600 11
2024 General $786 23
2023 General $1,460 82
2022 General $2,231 139
2021 General $2,416 162
2020 General $2,025 153
2019 General $1,850 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barry Brook
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Barry Brook were reported at $600. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Barry Brook Internal Medicine median Middle half National median
2019 $1,850 $159 $48–$570 $163
2020 $2,025 $119 $33–$402 $114
2021 $2,416 $135 $37–$521 $132
2022 $2,231 $141 $42–$496 $149
2023 $1,460 $149 $45–$519 $160
2024 $786 $154 $47–$537 $164
2025 $600 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,504 47 payments
  2. AbbVie, Inc. $1,218 61 payments
  3. Pfizer Inc. $1,182 98 payments
  4. Novo Nordisk Inc $1,020 79 payments
  5. GlaxoSmithKline, LLC. $689 69 payments
  6. Abbott Laboratories $656 29 payments
  7. Lilly USA, LLC $388 30 payments
  8. Novartis Pharmaceuticals Corporation $357 23 payments
  9. Janssen Pharmaceuticals, Inc $351 32 payments
  10. Merck Sharp & Dohme Corporation $347 27 payments
  11. Other $3,655 223 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,230 714 payments
  2. Education $115 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $862 68 payments
  2. FARXIGA $799 32 payments
  3. RYBELSUS $613 46 payments
  4. BREZTRI $605 9 payments
  5. QULIPTA $510 18 payments
  6. ELIQUIS $493 40 payments
  7. FreeStyle Libre 2 $439 17 payments
  8. TRELEGY ELLIPTA $392 44 payments
  9. XARELTO $342 30 payments
  10. Cologuard Collection Kit $294 15 payments
  11. Other $9,428 648 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 161 drugs

Part D claims

10,016

Median for Family Practice: 1,826

Drug cost

$675,068

Median for Family Practice: $120,094

Branded share of claims

24.6%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 228 $177,176
Farxiga Dapagliflozin Propanediol Brand 102 $84,602
Ozempic Semaglutide Brand 48 $53,000
Trulicity Dulaglutide Brand 30 $34,570
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $32,140
Xarelto Rivaroxaban Brand 35 $31,167
Jardiance Empagliflozin Brand 22 $29,209
Mounjaro Tirzepatide Brand 18 $19,667
Januvia Sitagliptin Phosphate Brand 13 $17,955
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 23 $16,775

The 10 drugs with the highest cost, of 161 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$140,788

Of which drugs: $36,294

Medicare patients

447

Average age 75

Services billed

1,835

208 women, 239 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 42%
Ischemic heart disease 27%
Diabetes 22%
Atrial fibrillation 21%
Chronic kidney disease 20%
Cancer 19%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 105 105 $30,448
Vaccine for influenza for injection into muscle 90653 Office 69 69 $5,646

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $340
$340 23 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $118
$118 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $31
$31 29 —
Crysvita
  • Ultragenyx Pharmaceutical Inc. $19
$19 — —
ABRYSVO
  • PFIZER INC. $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

718 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record